# Rifaximin and Propranolol Combination Therapy Versus Propranolol Monotherapy in Cirrhotic Patients

> **NCT01897051** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 140 (estimated)

## Conditions studied

- Liver Cirrhosis
- Portal Hypertension

## Interventions

- **DRUG:** Rifaximin + propranolol
- **DRUG:** Propranolol + Placebo

## Key facts

- **NCT ID:** NCT01897051
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-07
- **Primary completion:** 2017-02
- **Final completion:** 2017-06
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2015-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01897051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01897051, "Rifaximin and Propranolol Combination Therapy Versus Propranolol Monotherapy in Cirrhotic Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01897051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*